Search
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Ezatiostat
go.drugbank.com/drugs/DB05460InvestigationalIt acts intracellularly on the MAPK signaling pathway by activating ERK2. … It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common, toxic effect of many standard chemotherapeutic drugs.
Nuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada.
Ioxaglic acid
go.drugbank.com/drugs/DB09313ApprovedWithdrawnIoxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opa...
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in th...
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalUnlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.
Deoxyribonuclease I
go.drugbank.com/drugs/DB16523InvestigationalIt is normally found in saliva, urine, pancreatic secretions, and blood[A227723].
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424Investigationalof T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. … It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
IMM-101
go.drugbank.com/drugs/DB15850InvestigationalIt has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].